In 2005, a 1950s laboratory molecule that had never been approved for human use suddenly appeared on supplement store shelves across America, sitting right next to standard fitness products. Superdrol was not a questionable pre-workout formula or an overhyped protein powder. It was a potent, legitimate anabolic steroid legally sold alongside creatine and multivitamins, remaining accessible through various regulatory loopholes for more than six years after federal agencies first attempted to halt its distribution. What followed was a wave of dramatic muscle gains, a regulatory cat-and-mouse game involving dozens of rebranded products, and a growing number of young men hospitalized with severe, life-threatening liver damage.
The Molecule That Was Never Meant for Humans
Methasterone, the chemical name for Superdrol, first appeared in scientific literature in 1959 when researchers at Syntex published its synthesis in the Journal of the American Chemical Society. The same research team, in the very next paper of that same issue, described oxymetholone—better known today as Anadrol, another notoriously liver-toxic oral steroid still FDA-approved for treating anemia. But while Anadrol went on to clinical trials and eventual approval, methasterone was described as a potent orally active anabolic agent with only weak androgenic activity and then completely abandoned. No clinical trials were conducted, and no approvals were sought from health authorities. The molecule simply sat dormant in old chemistry journals for 45 years. Syntex already had injectable drostanolone, known as Masteron, on the market, which accomplished similar fitness goals without the hepatotoxic 17-alpha methyl group that makes oral steroids so harsh on the human liver.
How a Loophole Made Steroids Legal Supplements
Fast forward to 2005, and methasterone reappeared on the market as a dietary supplement called Superdrol, sold openly in mainstream stores. The Anabolic Steroid Control Act of 2004 had just placed numerous prohormones and steroid precursors into Schedule III, categorizing them alongside anabolic steroids and certain prescription medications. However, that legislation relied on a defined list of substances, and a forgotten molecule from 1959 that had never been marketed as a drug simply was not on federal regulators’ radar. The product label did not even display the chemical term methasterone; instead, it listed methasteron, a trademarked name devoid of an official chemical identity that regulators could immediately flag.
In November 2005, Dr. Don Catlin, who directed the U.S. Olympic drug testing laboratory at UCLA, analyzed five supplements purchased online at the request of The Washington Post. His analysis revealed that every single tested product contained actual steroids that would be highly effective in the human body. The Post published these findings on November 30, 2005, prompting the World Anti-Doping Agency to add methasterone to its prohibited list for 2006. Shortly after, on March 9, 2006, the Food and Drug Administration issued warning letters declaring these products to be unapproved new drugs. Yet, an FDA declaration labeling a substance an unapproved drug is not legally the same as the Drug Enforcement Administration placing it under formal controlled substance scheduling.
Six Years of Rebranding and Regulatory Chaos
Between 2006 and 2012, methasterone continuously reappeared under a revolving door of new names. Products including M-Drol, Masterdrol, Methyldrostanolone, and dozens of others flooded the market. One formal product recall alone listed 65 distinct products containing the compound. By March 2010, the DEA had identified approximately 62 additional methasterone-containing supplements still actively distributed to consumers. The actual DEA rule placing methasterone into Schedule III was not proposed until November 2011, finalized in July 2012, and did not officially take effect until August 29, 2012. Congress later reinforced the ban with the Designer Anabolic Steroid Control Act of December 2014, which named specific compounds directly rather than relying solely on agency action. For more than half a decade, the supplement industry successfully exploited gaps in federal coordination, allowing methasterone to circulate freely in a dangerous legal gray zone.
The Chemistry Behind the Hype
Superdrol is structurally very simple. The chemical pathway starts with dihydrotestosterone, a potent androgen naturally produced by the human body. Adding a methyl group at the 2-alpha position yields drostanolone, the injectable steroid Masteron, which is traditionally known for creating a dry, hard, and vascular appearance in bodybuilders. Adding a second methyl group at the 17-alpha position creates methasterone, or Superdrol. That second methyl group serves two distinct functions. First, it allows the drug to survive digestion and liver metabolism, rendering it orally active. Second, it dramatically increases the risk of liver toxicity. The 17-alpha methyl group blocks the specific enzyme that would normally inactivate the steroid on its initial pass through the liver, but that exact structural modification is also the feature most strongly associated with cholestatic liver injury across the entire class of anabolic steroids.
The 400-to-20 Ratio That Built a Reputation
Superdrol’s widespread mystique rested largely on a single reported metric: an anabolic-to-androgenic ratio of 400 to 20. Testosterone, the recognized reference standard, is rated 100 to 100. A ratio of 400 to 20 implied that Superdrol was four times as muscle-building and only one-fifth as androgenic as testosterone. Such a profile would have made it one of the most tissue-selective anabolic compounds ever described—essentially functioning as a selective androgen receptor modulator long before those substances became common. However, this ratio originated from unpublished rodent data summarized in a 1969 pharmacology reference book by Julius Vida. No peer-reviewed study has ever confirmed these numbers, and no published androgen receptor binding study for methasterone exists in indexed scientific literature. The DEA’s own summary of animal studies actually reported that methasterone’s affinity for the androgen receptor was comparable to testosterone rather than showing dramatic tissue selectivity.
Why It Worked So Why It Was Effective
Even without unique tissue selectivity, Superdrol undeniably worked, and users who purchased the compounds between 2005 and 2012 frequently recall its potency. Two key pharmacological features explain its efficacy. First, methasterone does not aromatize into estrogen. The 2-alpha methyl group blocks the aromatase enzyme, and because the molecule is already 5-alpha reduced, no biochemical pathway exists for estrogen conversion. This meant users experienced minimal water retention, no bloating, and no facial puffiness, often reporting a dry, hard, and vascular physique within days. Second, its oral bioavailability and strong binding affinity to androgen receptors led many users to report rapid gains of eight to ten pounds within a few weeks, accompanied by notable shifts in muscle density. With no injections or prescriptions required, the product achieved massive commercial success.
The Liver Damage No One Expected
The very structural modification that made Superdrol orally active also introduced severe physiological hazards. Recent research has identified a specific enzyme, AKR1D1, which plays a critical role in human bile acid metabolism by introducing a structural bend that allows bile acids to dissolve fats in the gut. Individuals born with natural mutations in this gene develop hepatic cholestasis and liver damage because their bile acids fail to fold correctly. A 2023 study screening several anabolic steroids discovered that methasterone, alongside nandrolone, drostanolone, and methenolone, inhibits AKR1D1. When this enzyme is blocked, bile acids become chemically flat and lose functionality. Bile flow slows significantly, turning into a sludge-like consistency, while bilirubin—a breakdown product of red blood cells—backs up directly into the bloodstream, causing clinical jaundice.
Furthermore, some individuals carry genetic variants in ABCB11, the gene responsible for the bile salt export pump, making them exceptionally vulnerable to this specific form of hepatic injury. Because there is no standard way to identify these genetic risk factors beforehand, most casual users experienced no immediate issues, while vulnerable individuals often remained unaware of the danger until weeks after they had finished taking the drug.
Clinical Outcomes and Medical Case Reports
Real-world medical case reports illustrate a consistent and concerning pattern of injury. The first documented case emerged in 2006, involving a man who used an over-the-counter muscle builder and presented with cholestatic jaundice alongside IgA nephropathy, a serious combined liver and kidney condition. By 2008, hospital case reviews outlined a troubling timeline. Users typically developed jaundice roughly two weeks after they stopped taking the substance. They sought medical attention two weeks later, at which point bilirubin levels continued climbing for an additional two to three weeks before finally peaking, with full physical recovery requiring approximately 12 weeks of supportive medical care.
A 2019 clinical study examined 44 young men, with an average age of 33, who were hospitalized due to liver injuries stemming from bodybuilding supplements. The median time elapsed from first use to the onset of physical symptoms was 73 days. Every single patient presented with jaundice, 84 percent experienced severe, debilitating itching, and 71 percent required formal hospital admission. Liver biopsies revealed profound cholestasis accompanied by only mild inflammation, noting a distinct absence of bile duct injury, duct loss, or tissue fibrosis. A subsequent 2020 systematic review in the United Kingdom analyzing 52 cases identified methyldrostanolone as the single most frequent agent responsible for supplement-induced liver injury, with peak bilirubin levels averaging approximately 34 times the normal physiological upper limit.
When Liver Complications Cascade Into Kidney Failure
Clinical analyses from international liver injury registries have identified a critical connection between severe cholestatic events and acute kidney injury, driven largely by elevated bilirubin levels. When bilirubin rises excessively, both bilirubin and accumulated bile acids can physically block kidney tubules, leading to a condition known as bile cast nephropathy. In the United Kingdom case series, 43 percent of affected patients developed secondary acute kidney injury, with some cases requiring temporary hemodialysis. Additional international case reports have documented patients requiring both hemodialysis and plasma exchange following methasterone exposure.
Despite the severity of these medical emergencies, most patients eventually recovered with supportive hospital care, and published literature records no associated fatalities or required liver transplants. However, recovery frequently entailed enduring two to three months of severe jaundice, sleep-disrupting itching, and potential renal complications without any targeted pharmaceutical treatment available to accelerate the healing process.
The Persistence of Dangerous Over-the-Counter Myths
Many historical and contemporary users believed they could successfully offset the hepatic strain of Superdrol by combining it with over-the-counter liver support supplements. Medical science indicates that no dietary supplement is proven to prevent methasterone-induced cholestasis, nor are there proven pharmacological treatments available once the condition develops. Physicians managing these cases rely entirely on supportive care while waiting for the liver to regenerate on its own. The persistent belief that standard retail supplements can neutralize a potent anabolic steroid remains a significant hazard in performance enhancement culture.
Current Regulatory and Public Health Status
Methasterone remains classified as a Schedule III controlled substance in the United States, making the unauthorized manufacture, distribution, or possession of the compound illegal without a valid medical prescription. Despite federal scheduling, the substance continues to circulate on illicit markets and occasionally appears in professional anti-doping test results. Both methasterone and oxymetholone have frequently ranked among the substances detected in adverse analytical findings reported by anti-doping authorities in recent years. While the compound demonstrated biological potency, medical literature highlights a profound disparity between its physical effectiveness and its safety profile, leaving healthcare professionals to manage the lasting health consequences of a long-abandoned laboratory molecule.
